ACP3-targeted PET/CT imaging to detect prostate cancer lesions

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

ACP3 is a novel PET radiotracer designed to target prostate cancer lesions. Participants undergo contemporaneous ACP3 PET/CT alongside standard-of-care PSMA/FDG PET/CT for initial staging, detection of metastases, or suspected recurrence. Tumor uptake will be quantified using SUVmax and the number of positive lesions will be recorded by visual interpretation. Diagnostic accuracy of ACP3 PET/CT will be calculated and compared directly with the standard imaging methods.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult patients (aged 18 years or older);
* Patients with newly diagnosed, highly suspected recurrence or previously treated metastases of prostate cancer (supporting evidence may include MRI, CT, tumor markers, and pathology report);
* Patients who had scheduled both standard-of-care imaging (PSMA/FDG PET/CT) and ACP3 PET/CT scans;
* Patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.

Exclusion Criteria:

* The inability or unwillingness of the research participant or legal representative to provide written informed consent.

Where it's running

• The First Affliated Hospital of Guilin Medical University
  Guilin, Guangxi, China Recruiting

Study contacts

• Study coordinator: Xingyu Mu, PhD
• Email: muxingyu1992@hotmail.com
• Phone: 86 13347631119

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• 68Ga-XMFH01 PET/FL imaging to guide prostate cancer surgery

  This study tests a new dual-modality imaging probe, 68Ga-XMFH01, to preoperatively detect prostate cancer and guide the surgeon with fluorescence during operations in adults with newly diagnosed prostate cancer.

  Recruiting The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT07885423

• Hugo Robotic Prostatectomy in an Ambulatory Surgery Center

  This study tests the use of the Hugo robotic system for prostate removal in adult men treated at an outpatient surgical center.

  Recruiting Central Ohio Urology Group · Columbus, Ohio · NCT07875192

• Adaptive intraoperative biopsy system for prostate cancer using imaging and metabolic feedback

  Aiming to test a smart biopsy approach that combines preoperative imaging with real-time metabolic signals to guide where to take prostate biopsy cores for better precision in men suspected of prostate cancer.

  Recruiting at 4 sites Shanghai Zhongshan Hospital · Shanghai and 3 other locations · NCT07856017

• miRNA panel test to help diagnose prostate cancer

  A blood test using a microRNA panel is being tested to help diagnose prostate cancer in men who are suspected of having the disease.

  Recruiting RenJi Hospital · Shanghai · NCT07755592

• Testing 68Ga-NYM032 PET/CT in men with newly diagnosed prostate cancer

  This study tests a new PSMA-targeted PET/CT imaging agent to see if it safely and accurately locates cancer in men who have just been diagnosed with prostate cancer and are planned for surgery.

  Recruiting at 2 sites Phase 3 Norroy Bioscience Co., LTD · Nanjing, Jiangsu and 1 other locations · NCT07615101

• Multi-Modal Imaging and Digital Pathology to Predict Clinically Significant Prostate Cancer

  A multi-center study tests a deep learning model that combines MRI, ultrasound, and digital pathology to see if it can predict clinically significant prostate cancer non-invasively and help guide biopsies.

  Recruiting Guangxi Medical University · Liuzhou, Guangxi · NCT07614256

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.